Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 2 (2005), Issue 1 (January)

1. Modulation of effective connectivity inside the working memory network in patients at the earliest stage of multiple sclerosis.
   Neuroimage, 24(2): 533-8. [Abstract] [Full-text]
2. Acute tinnitus and hearing loss as the initial symptom of multiple sclerosis in a child.
   Int J Pediatr Otorhinolaryngol, 69(1): 123-6. [Abstract] [Full-text]
3. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.
   J Clin Invest, 115(1): 187-94. [Abstract] [Full-text]
4. Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse.
   Eur Neurol, 52(4): 237-41. [Abstract] [Full-text]
5. Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran.
   Eur Neurol, 52(4): 202-6. [Abstract] [Full-text]
6. Prevalence and correlates of depression among veterans with multiple sclerosis.
   Neurology, 64(1): 75-80. [Abstract] [Full-text]
7. Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker.
   Arch Neurol, 62(1): 33-6. [Abstract] [Full-text]
8. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
   J Neurol, 251(12): 1502-6. [Abstract] [Full-text]
9. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b.
   J Neurol, 251(12): 1498-501. [Abstract] [Full-text]
10. European validation of a standardized clinical description of multiple sclerosis.
    J Neurol, 251(12): 1472-80. [Abstract] [Full-text]
11. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient.
    J Eur Acad Dermatol Venereol, 19(1): 112-3. [Abstract] [Full-text]
12. Spatio-temporal selectivity of loss of colour and luminance contrast sensitivity with multiple sclerosis and optic neuritis.
    Ophthalmic Physiol Opt, 25(1): 57-65. [Abstract] [Full-text]
13. Timing of birth and risk of multiple sclerosis: population based study.
    BMJ, 330(7483): 120. [Abstract] [Full-text]
14. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study.
    J Neurol, 252(1): 8-13. [Abstract] [Full-text]
15. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence.
    J Neurol Neurosurg Psychiatry, 76(2): 272-5. [Abstract] [Full-text]
16. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
    J Neurol Neurosurg Psychiatry, 76(2): 206-11. [Abstract] [Full-text]
17. Extraction and proteomic analysis of proteins from normal and multiple sclerosis postmortem brain.
    J Chromatogr B Analyt Technol Biomed Life Sci, 815(1): 191-202. [Abstract] [Full-text]
18. CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese.
    J Neuroimmunol, 159(1): 225-9. [Abstract] [Full-text]
19. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    J Neuroimmunol, 159(1): 155-64. [Abstract] [Full-text]
20. Oligoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis.
    J Neuroimmunol, 159(1): 133-6. [Abstract] [Full-text]
21. Increased thrombin inhibition in experimental autoimmune encephalomyelitis.
    J Neurosci Res, 79(3): 351-9. [Abstract] [Full-text]
22. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma.
    J Exp Med, 201(2): 195-200. [Abstract] [Full-text]
23. Cerebellar dysfunction in multiple sclerosis: evidence for an acquired channelopathy.
    Prog Brain Res, 148: 353-65. [Abstract] [Full-text]
24. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis.
    Annu Rev Med, 56: 273-302. [Abstract] [Full-text]
25. The neuro-ophthalmology of multiple sclerosis.
    Lancet Neurol, 4(2): 111-21. [Abstract] [Full-text]
26. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis.
    Brain, 128: 375-85. [Abstract] [Full-text]
27. Repeated injuries dramatically affect cells of the oligodendrocyte lineage: effects of PDGF and NT-3 in vitro.
    Glia, 49(4): 555-66. [Abstract] [Full-text]
28. Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis.
    Hum Brain Mapp, 24(3): 216-28. [Abstract] [Full-text]
29. The HLA locus and multiple sclerosis in Sicily.
    Neurology, 64(2): 361-3. [Abstract] [Full-text]
30. The association of depression with disease course in multiple sclerosis.
    Neurology, 64(2): 359-60. [Abstract] [Full-text]
31. Effect of corticosteroids on short-term and long-term memory.
    Neurology, 64(2): 335-7. [Abstract] [Full-text]
32. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.
    Neurology, 64(2): 236-40. [Abstract] [Full-text]
33. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis.
    Eur J Neurol, 11(12): 833-4. [Abstract] [Full-text]
34. Exposure to infant siblings during early life and risk of multiple sclerosis.
    JAMA, 293(4): 463-9. [Abstract] [Full-text]
35. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI.
    Neuroimage, 24(4): 1139-46. [Abstract] [Full-text]
36. Exercise therapy for multiple sclerosis.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
37. The role of edema and demyelination in chronic T1 black holes: a quantitative magnetization transfer study.
    J Magn Reson Imaging, 21(2): 103-10. [Abstract] [Full-text]
38. Association of haplotypes in the beta-chemokine locus with multiple sclerosis.
    Eur J Hum Genet, 13(2): 240-7. [Abstract] [Full-text]
39. Addressing the specialized needs of younger adults with multiple sclerosis.
    Case Manager, 16(1): 66-9. [Abstract] [Full-text]
40. Is optic neuritis more benign than other first attacks in multiple sclerosis?
    Ann Neurol, 57(2): 210-5. [Abstract] [Full-text]
41. Plasma membrane calcium ATPase deficiency causes neuronal pathology in the spinal cord: a potential mechanism for neurodegeneration in multiple sclerosis and spinal cord injury.
    FASEB J, 19(2): 298-300. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.